XNASCMPS
Market cap324mUSD
Jan 07, Last price
4.63USD
1D
6.74%
1Q
-21.23%
IPO
-83.52%
Name
Compass Pathways PLC
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
24.21%
Rev. gr., 5y
%
Revenues
0k
Net income
-118m
L+29.46%
CFO
-97m
L-7.66%
Earnings
Feb 26, 2025
Profile
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 137,162 | 110,733 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (137,162) | (110,733) | ||||
NOPBT Margin | ||||||
Operating Taxes | 780 | 408 | ||||
Tax Rate | ||||||
NOPAT | (137,942) | (111,141) | ||||
Net income | (118,464) 29.46% | (91,505) 27.55% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 144,935 | 440 | ||||
BB yield | -32.46% | -0.13% | ||||
| Debt | ||||||
Debt current | 4,822 | 1,510 | ||||
Long-term debt | 34,932 | 2,346 | ||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (180,913) | (139,819) | ||||
| Cash flow | ||||||
Cash from operating activities | (97,376) | (105,451) | ||||
CAPEX | (66) | (596) | ||||
Cash from investing activities | (64) | (596) | ||||
Cash from financing activities | 173,830 | 1,040 | ||||
FCF | (132,018) | (134,844) | ||||
| Balance | ||||||
Cash | 220,198 | 143,206 | ||||
Long term investments | 469 | 469 | ||||
Excess cash | 220,667 | 143,675 | ||||
Stockholders' equity | (395,901) | (277,573) | ||||
Invested Capital | 657,106 | 460,614 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 51,028 | 42,436 | ||||
Price | 8.75 8.97% | 8.03 -63.67% | ||||
Market cap | 446,495 31.03% | 340,763 -61.45% | ||||
EV | 265,582 | 200,944 | ||||
EBITDA | (136,920) | (110,403) | ||||
EV/EBITDA | ||||||
Interest | 2,213 | 6,033 | ||||
Interest/NOPBT | ||||||